Official_Bellicum_Logo_RGB.jpg
Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market
December 06, 2021 07:30 ET | Bellicum Pharmaceuticals, Inc.
- Confirmed partial response observed in one patient in first cohort of metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 - - Favorable safety profile observed in...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update
November 04, 2021 16:05 ET | Bellicum Pharmaceuticals, Inc.
- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology - - Charity Scripture, MS, PharmD, appointed Chief...
Official_Bellicum_Logo_RGB.jpg
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 03, 2021 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick...
Official_Bellicum_Logo_RGB.jpg
Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch
September 01, 2021 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Second Quarter 2021 Financial Results and Provides Operational Update
August 12, 2021 16:05 ET | Bellicum Pharmaceuticals, Inc.
- Entered into a licensing agreement with two leading oncology research and treatment centers for use of CaspaCIDe® safety switch technology - - Enrollment continuing in Phase 1/2 dose-escalation...
Official_Bellicum_Logo_RGB.jpg
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 26, 2021 17:25 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced an equity...
Official_Bellicum_Logo_RGB.jpg
Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch
June 28, 2021 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it has...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update
May 17, 2021 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update
March 30, 2021 16:05 ET | Bellicum Pharmaceuticals, Inc.
Enrolled first patient in Phase 1/2 clinical trial for BPX-603 in solid tumors that express HER2 Clinical hold lifted on Phase 1/2 dose-escalation trial evaluating BPX-601 and rimiducid in...
Official_Bellicum_Logo_RGB.jpg
Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
March 23, 2021 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will...